Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 16/20 | 0.57 |
| ▸ | METTL14 | Q9HCE5 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30433211 | 0.77 | METTL3 (0.62) | METTL3METTL14KDM4EADORA3ADORA2A | |
| SCHEMBL30432671 | 0.77 | RXFP1 (0.52) | METTL3METTL14KDM4EADORA3ADORA2A | |
| SCHEMBL30433994 | 0.77 | RXFP1 (0.52) | METTL3METTL14KDM4EADORA3ADORA2A | |
| SCHEMBL30433498 | 0.76 | METTL3 (0.58) | METTL3KDM4EADORA3ADORA2AADORA2B | |
| SCHEMBL30132372 | 0.75 | PKM (0.57) | METTL3KDM4EADORA3ADORA2AADORA2B | |
| SCHEMBL30433464 | 0.75 | METTL3 (0.50) | METTL3KDM4EADORA3ADORA2AADORA2B | |
| SCHEMBL22499166 | 0.74 | METTL3 (1.00) | METTL3METTL14 | |
| SCHEMBL22498826 | 0.74 | METTL3 (1.00) | METTL3METTL14 | |
| SCHEMBL30433263 | 0.74 | METTL3 (0.56) | METTL3METTL14KDM4E | |
| SCHEMBL22499308 | 0.73 | METTL3 (1.00) | METTL3METTL14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (US) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | HAVCR2, HMBS, VHL | METTL3 773/4885METTL14 2555/4885KDM4E 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.